NEOGENOMICS INC (NEO) Stock Fundamental Analysis
USA - NASDAQ:NEO - US64049M2098 - Common Stock
10.41 USD
+0.19 (+1.86%)
10.41 USD
0 (0%)
Taking everything into account, NEO scores 3 out of 10 in our fundamental rating. NEO was compared to 100 industry peers in the Health Care Providers & Services industry. While NEO seems to be doing ok healthwise, there are quite some concerns on its profitability. NEO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NEO had positive earnings in the past year.
In the past year NEO had a positive cash flow from operations.
NEO had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NEO reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of NEO (-8.25%) is worse than 74.00% of its industry peers.
The Return On Equity of NEO (-13.54%) is worse than 62.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.25% | ||
| ROE | -13.54% | ||
| ROIC | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NEO has a better Gross Margin (43.46%) than 72.00% of its industry peers.
In the last couple of years the Gross Margin of NEO has declined.
NEO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
2. Health
2.1 Basic Checks
NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
NEO has more shares outstanding than it did 1 year ago.
NEO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NEO has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.59, we must say that NEO is in the distress zone and has some risk of bankruptcy.
NEO's Altman-Z score of 1.59 is on the low side compared to the rest of the industry. NEO is outperformed by 60.00% of its industry peers.
NEO has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
NEO has a better Debt to Equity ratio (0.41) than 64.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.59 |
ROIC/WACCN/A
WACC7.75%
2.3 Liquidity
NEO has a Current Ratio of 3.91. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
NEO has a Current ratio of 3.91. This is amongst the best in the industry. NEO outperforms 89.00% of its industry peers.
NEO has a Quick Ratio of 3.62. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
NEO has a Quick ratio of 3.62. This is amongst the best in the industry. NEO outperforms 89.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.11% over the past year.
NEO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -20.25% yearly.
NEO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.10%.
NEO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.07% yearly.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%-40%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%11.9%
3.2 Future
NEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.70% yearly.
Based on estimates for the next years, NEO will show a quite strong growth in Revenue. The Revenue will grow by 9.43% on average per year.
EPS Next Y-12.63%
EPS Next 2Y31.64%
EPS Next 3Y56.98%
EPS Next 5Y45.7%
Revenue Next Year9.42%
Revenue Next 2Y9.63%
Revenue Next 3Y9.49%
Revenue Next 5Y9.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 104.10, the valuation of NEO can be described as expensive.
The rest of the industry has a similar Price/Earnings ratio as NEO.
When comparing the Price/Earnings ratio of NEO to the average of the S&P500 Index (25.56), we can say NEO is valued expensively.
NEO is valuated quite expensively with a Price/Forward Earnings ratio of 60.07.
NEO's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.62, NEO is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 104.1 | ||
| Fwd PE | 60.07 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NEO's earnings are expected to grow with 56.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.64%
EPS Next 3Y56.98%
5. Dividend
5.1 Amount
NEO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.41
+0.19 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners100.35%
Inst Owner Change1.05%
Ins Owners1.17%
Ins Owner Change4.47%
Market Cap1.34B
Revenue(TTM)709.16M
Net Income(TTM)-113.47M
Analysts71.58
Price Target10.25 (-1.54%)
Short Float %5.63%
Short Ratio1.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.29%
Min EPS beat(2)31.6%
Max EPS beat(2)40.97%
EPS beat(4)4
Avg EPS beat(4)51.9%
Min EPS beat(4)31.6%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)207.03%
EPS beat(12)12
Avg EPS beat(12)159.81%
EPS beat(16)16
Avg EPS beat(16)125.04%
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.73%
Max Revenue beat(2)1.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.22%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)1.18%
Revenue beat(8)4
Avg Revenue beat(8)-0.08%
Revenue beat(12)8
Avg Revenue beat(12)2.05%
Revenue beat(16)10
Avg Revenue beat(16)1.77%
PT rev (1m)4.74%
PT rev (3m)18.82%
EPS NQ rev (1m)-14.2%
EPS NQ rev (3m)-19.39%
EPS NY rev (1m)-5.02%
EPS NY rev (3m)-45.51%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-0.28%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)-2.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 104.1 | ||
| Fwd PE | 60.07 | ||
| P/S | 1.9 | ||
| P/FCF | N/A | ||
| P/OCF | 98.48 | ||
| P/B | 1.6 | ||
| P/tB | 67.97 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.1
EY0.96%
EPS(NY)0.17
Fwd EY1.66%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)0.11
OCFY1.02%
SpS5.49
BVpS6.49
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.25% | ||
| ROE | -13.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.46% | ||
| FCFM | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 44.15% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.62 | ||
| Altman-Z | 1.59 |
F-Score4
WACC7.75%
ROIC/WACCN/A
Cap/Depr(3y)46.9%
Cap/Depr(5y)68.48%
Cap/Sales(3y)5.71%
Cap/Sales(5y)7.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%-40%
EPS Next Y-12.63%
EPS Next 2Y31.64%
EPS Next 3Y56.98%
EPS Next 5Y45.7%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%11.9%
Revenue Next Year9.42%
Revenue Next 2Y9.63%
Revenue Next 3Y9.49%
Revenue Next 5Y9.43%
EBIT growth 1Y-6.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.86%
EBIT Next 3Y41.96%
EBIT Next 5Y28.43%
FCF growth 1Y65.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y158.31%
OCF growth 3YN/A
OCF growth 5Y-21.37%
NEOGENOMICS INC / NEO FAQ
What is the fundamental rating for NEO stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEO.
What is the valuation status of NEOGENOMICS INC (NEO) stock?
ChartMill assigns a valuation rating of 1 / 10 to NEOGENOMICS INC (NEO). This can be considered as Overvalued.
How profitable is NEOGENOMICS INC (NEO) stock?
NEOGENOMICS INC (NEO) has a profitability rating of 1 / 10.
What are the PE and PB ratios of NEOGENOMICS INC (NEO) stock?
The Price/Earnings (PE) ratio for NEOGENOMICS INC (NEO) is 104.1 and the Price/Book (PB) ratio is 1.6.
Can you provide the financial health for NEO stock?
The financial health rating of NEOGENOMICS INC (NEO) is 4 / 10.